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ABSTRACT 
The objective of the method was to develop a simple, rapid, sensitive, precise, accurate and validated Ultra Performance Liquid Chromatographic 
(UPLC) method for the estimation of Ticagrelor in tablet dosage form. Chromatographic separation was achieved on an acquity UPLC BDS C8 
(150 x 4.6 mm, 5) column with a mobile phase composed of Buffer 0.1% OPA (2.2 pH) and  Acetonitrile  in the ratio of 60:40   at a flow rate of 
1.0 ml/min and 1 μl injection volume. The effluents were detected at a wavelength of 240 nm using TUV detector. The retention time of 
Ticagrelor was  found to be at 0.942 min. %RSD of the Ticagrelor was found to be 0.7  The method was validated with respect to specificity, 
accuracy, linearity, precision, robustness. The correlation coefficient for Ticagrelor was found to be 0.999. Recovery of Ticagrelor in formulation 
was found to be 99.51% . LOD, LOQ values obtained from regression equations of Ticagrelor were 0.45, 1.35 respectively.  Due to simplicity, high 
precision and rapidness the method can be successfully applied for   estimation of Ticagrelor in tablet dosage form. 
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1. INTRODUCTION 
Ticagrelor, (1S,2S,3R,5S) – 3 - (7-{[(1R,2S) – 2 -(3,4difluoro 
phenyl) cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3] 
triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy) 
cyclopentane-1,2-diol  is a platelet aggregation inhibitor . 
Like the thienopyridines prasugrel, clopidogrel and 
ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) 
receptors of subtype P2Y12. In contrast to the other 
antiplatelet drugs, ticagrelor has a binding site different from 
ADP, making it an allosteric antagonist, and the blockage is 
reversible. Moreover, the drug does not need hepatic 
activation, which might work better for patients with genetic 
variants regarding the enzyme CYP2C19 (although it is not 
certain whether clopidogrel is significantly influenced by 
such variants). The structure of Ticagrelor was shown in Fig. 
1. 
The literature survey revealed that there are few   RP-HPLC1-
4   and UV5-7     methods are available for the   estimation of 
Ticagrelor .  However, a stability indicating UPLC method 
was not available. Hence, present work focused on the 
development and validation of a simple, rapid, robust and 
economical stability indicating UPLC method. To the best of 
our knowledge the anticipated method is the first UPLC 
method to allow   estimation of Ticagrelor in tablet dosage 
form. 
 
 
Figure 1: Chemical Structure Of Ticagrelor 
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2. MATERIALS AND METHODS  
2.1 RP-HPLC method 
2.1.1 Apparatus: The separation was carried on Waters 
Acquity UPLC 2996 with Empower 2 software that consisted 
of a binary solvent manager equipped with automatic 
sampler. An acquity UPLC Hibra C18 2.1 ×100 mm, 1.8 μ 
column was used for separation of active ingredients. 
Analytes were monitored with TUV detector at a wavelength 
222 nm. Ultrasonicator was used to remove dissolved gases 
and air bubbles in the mobile phase.  
2.1.2 Materials: Ticagrelor standard sample was obtained 
as gift samples from Spectrum Labs, Hyderabad. HPLC grade 
water and methanol were purchased from Merck Ltd., 
Mumbai. Analytical grade acetonitrile and orthophosphoric 
acid were obtained from Rankem, Avantor Performance 
Material India Ltd. Marketed formulation of combination was 
purchased from local market. 
2.1.3 Chromatographic Conditions: Separation of analytes 
was achieved with a mobile phase consisting of 0.1% OPA 
and acetonitrile at a ratio of 50:40 delivered at a flow rate of 
0.3ml/min through column kept at 25 ºC. The volume of 
injection was 1 μl and runtime was 2min. The eluents were 
detected at a wavelength 260 nm. Chromatograms of   
optimized method and standard were shown Fig. 2 and Fig. 
3.
 
 
Figure 2: Chromatogram of optimized method 
 
Figure 3: Chromatogram of standard preparation 
2.1.4 Preparation of Standard stock solutions: Accurately 
weighed 15mg of Ticagrelor transferred to individual 25 ml 
volumetric flasks separately. 3/4 th of diluents was added to 
both of these flasks and sonicated for 10 minutes. Flasks 
were made up with diluents and labeled as Standard stock 
solution. (600µg/ml of Ticagrelor) . 1ml from each stock 
solution was pipetted out and taken into a 10ml volumetric 
flask and made up with diluent. (60µg/ml Ticagrelor) 
2.1.5 Preparation of Sample stock solutions: 5 tablets 
were weighed and the average weight of each tablet was 
calculated, then the weight equivalent to 1 tablet was 
transferred into a 100 ml volumetric flask, 50ml of diluents 
was added and sonicated for 25 min, further the volume was 
made up with diluent and filtered by HPLC filters (600µg/ml 
of Ticagrelor). 1ml of filtered sample stock solution was 
transferred to 10ml volumetric flask and made up with 
diluent. (60µg/ml of Ticagrelor). 
2.2 Validation of the HPLC method 8-11 
2.2.1. System suitability 
The developed method was validated according to ICH 
guidelines8. To check the system performance, the system 
suitability parameters were measured. System precision was 
determined on six replicate injections of standard 
preparations. Number of theoretical plates and asymmetry 
were measured9-10 
The system suitability parameters were determined by 
preparing standard solutions of Ticagrelor (60ppm) and the 
solutions were injected six times and the parameters like 
peak tailing, resolution and USP plate count were 
determined. The % RSD for the area of six standard 
injections results should not be more than 2%. 
2.2.2 Linearity  
Accurately weighed 15mg of Ticagrelor transferred to 
individual 25 ml volumetric flasks separately. 3/4 th of 
diluents was added to both of these flasks and sonicated for 
10 minutes. Flasks were made up with diluents and labeled 
as Standard stock solution. (600µg/ml of Ticagrelor).  The 
calibration graphs were plotted over 5 different linear 
concentrations in the range of 15-150  g/mL for ticagrelor. 
2.2.3 Accuracy  
Accuracy is the percent of analyte recovered by assay from a 
known added amount. For the measurement of accuracy data 
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from nine determinations over three concentration levels 
covering the specified range were determined. 
2.2.4 Precision 
 Precision is the degree of repeatability of an analytical 
method under normal operational conditions. The precision 
of the assay was determined by repeatability (intra-day) and 
intermediate precision (inter-day) and reported as % R.S.D. 
for a statistically significant number of replicate 
measurements. The intermediate precision was studied by 
comparing the assays on 3 different days and the results 
documented as standard deviation and %R.S.D11. 
2.2.5 LOD and LOQ 
 The limit of detection (LOD) is defined as the lowest 
concentration of an analyte that an analytical process can 
reliably differentiate from background levels. The limit of 
quantification (LOQ) is defined as the lowest concentration 
of the standard curve that can be measured with acceptable 
accuracy, precision and variability (ICH guideline Q2B, 
2005).   
2.2.6 Robustness  
The robustness of the method was evaluated by assaying the 
test solutions after slight but deliberate changes in the 
analytical condition ns like flow rate (+0.1 mL min−1), and 
mobile phase composition (2%). 
3. RESULT AND DISCUSSION  
3.1 System suitability 
Ticagrelor was eluted at 0.947 min respectively with good 
resolution. Plate count and tailing factor was very 
satisfactory, so this method was optimized and to be 
validated.   
Table 1: System suitability 
S: no  Ticagrelor 
Inj RT(min) USP Plate Count Tailing 
1 0.940 4206 1.6 
2 0.941 4222 1.6 
3 0.941 4204 1.6 
4 0.941 4200 1.6 
5 0.941 4209 1.6 
6 0.942 4176 1.6 
 
According to the USP, the HPLC method is considered 
suitable when the ticagrelor of peak area ˂1%, tailing factor 
˂2 and the theoretical plates ˃2000.    
All the system suitability parameters were within the range 
and satisfactory as per ICH guidelines. The results of system 
suitability are shown in Table 1. 
3.2 Linearity 
Six linear concentrations of Ticagrelor (15-90µg/ml) was 
injected in a duplicate manner. Average areas were 
mentioned above and linearity equations obtained for 
Ticagrelor was y = 7237.7.x + 1401.1. Correlation coefficient 
obtained was 0.999 for the drug. The regression analysis is 
shown in table 2. 
Table 2: Regression analysis 
Ticagrelor 
Conc   (μg/mL) Peak area 
0 0 
15 109870 
30 219188 
45 329037 
60 437619 
75 540777 
90 653198 
  
 
Figure 2: Calibration Graph of Ticagrelor 
3.3 Accuracy  
Three levels of Accuracy samples were prepared by standard 
addition method. Triplicate injections were given for each 
level of accuracy and mean %Recovery was obtained as 
99.51% for Ticagrelor respectively. 
 
Table 3: Recovery studies of Ticagrelor 
%  Level  
Amount 
Spiked(μg/mL) 
Amount recovered 
(μg/mL) % Recovery  Mean % Recovery  
50%  
30 30.25 100.84 
 
 
 
 
   99.51% 
 
30 29.42 98.06 
30 29.92 99.73 
100%  
60 60.12 100.20 
60 59.47 99.12 
60 59.51 99.19 
150%  
90 88.67 98.52 
90 89.31 99.24 
90 90.62 100.69 
 
3.4 Precision 
 Multiple sampling from a sample stock solution was done 
and six working sample solutions of same concentrations 
were prepared, each injection from each working sample 
solution was given and obtained areas were mentioned in 
the above table. Average area, standard deviation and % RSD 
y = 7237.7x + 1401.1 
R² = 0.9999 
0 
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were calculated for drug and obtained as 0.7% respectively 
for Ticagrelor. As the limit of Precision was less than “2” the 
system precision was passed in this method. 
Table 4:  Repeatability table of Ticagrelor 
S. No Area of Ticagrelor 
1. 439649 
2. 434070 
3. 438841 
4. 431807 
5. 433398 
6. 436850 
Mean 435769 
S.D 3158.0 
%RSD 0.7 
 
Limit of Detection and Limit of Quantification (LOD and 
LOQ): The limit of detection is the point at which a measured 
value is larger than the uncertainty associated with it. It is 
the lowest concentration of analyte in a sample that can be 
detected but not necessarily quantified.  
Table 5: LOD and LOQ results of ticagrelor 
Molecule Ticagrelor 
  LOD 0.45 
  LOQ 1.33 
 
The limit of quantitation is the lowest injected amount that 
produces quantitative measurements in the target matrix 
with acceptable precision in chromatography. The 
quantitative limit is particularly used for the determination 
of impurities and degradation products. The results were 
shown in Table 5. 
3.5 Robustness 
Robustness conditions like Flow minus (0.27ml/min), Flow 
plus (0.33ml/min), mobile phase minus (55B:45A), mobile 
phase plus (65B:35A), temperature minus (25°C) and 
temperature plus (35°C) was maintained and samples were 
injected in duplicate manner. System suitability parameters 
were not much affected and all the parameters were passed. 
%RSD was within the limit. 
Table 6: Robustness data for Ticagrelor 
S.no Condition %RSD of Ticagrelor 
1 Flow rate (-) 0.27ml/min 0.4 
2 Flow rate (+) 0.33ml/min 1.1 
3 Mobile phase (-) 55B:45A 0.5 
4 Mobile phase (+) 65B:35A 0.8 
5 Temperature (-) 25°C 0.4 
6 Temperature (+) 35°C 0.7 
 
Assay: (Brilinta) bearing the label claim Ticagrelor 60mg, 
Assay was performed with the above formulation. Average % 
Assay for Ticagrelor obtained was 99.9% and shown in table 
7.
 
Table 7: Assay Data of Ticagrelor 
S.no Standard Area Sample area % Assay 
1 433305 439649 100.76 
2 428777 434070 99.48 
3 434092 438841 100.57 
4 438930 431807 98.96 
5 441475 433398 99.32 
6 436287 436850 100.11 
Avg 435478 435769 99.9 
Stdev 4473.9 3158.0 0.7 
%RSD 1.0 0.7 0.7 
 
Forced Degradation Studies: Forced degradation studies 
were conducted to know the stability of the method. The 
degradation studies were carried out by applying various 
stress conditions for the product like acid stress, base stress, 
UV stress, humidity stress, thermal stress and oxide stress. 
Degradation peaks were observed only in acid stress and 
peroxide stress and all degradation peaks were well resolved 
from analyte peaks. The results of forced degradation studies 
were shown in Table 8. 
  
Table 8: results of forced degradation studies 
Type of 
degradation  
                       Ticagrelor 
AREA %RECOVERED % DEGRADED 
Acid  415118 95.13 4.87 
  Base 409117 93.76 6.24 
Peroxide 419117 96.05 3.95 
Thermal 428139 98.12 1.88 
Uv  429780 98.49 1.51 
Water 434865 99.66 0.34 
 
CONCLUSION 
The developed UPLC analytical method provides an 
ecofriendly, reliable, reproducible, simple, rapid, sensitive, 
accurate, precise and specific assay method for the 
simultaneous estimation of Ticagrelor in pharmaceutical 
formulations. Degradation studies reveal that the developed 
method was stability indicating. Hence the proposed method 
can be conveniently used for the routine analysis of 
Ticagrelor in pure and pharmaceutical dosage forms. 
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